Skip Navigation
Alexis Madrigal

Alexis Madrigal - Alexis Madrigal is a senior editor at The Atlantic. He's the author of Powering the Dream: The History and Promise of Green Technology.
More

The New York Observer calls him, "for all intents and purposes, the perfect modern reporter." Madrigal co-founded Longshot magazine, a high-speed media experiment that garnered attention from The New York Times, The Wall Street Journal, and the BBC. While at Wired.com, he built Wired Science into one of the most popular blogs in the world. The site was nominated for best magazine blog by the MPA and best science Web site in the 2009 Webby Awards. He also co-founded Haiti ReWired, a groundbreaking community dedicated to the discussion of technology, infrastructure, and the future of Haiti.

He's spoken at Stanford, CalTech, Berkeley, SXSW, E3, and the National Renewable Energy Laboratory, and his writing was anthologized in Best Technology Writing 2010 (Yale University Press).

Madrigal is a visiting scholar at the University of California at Berkeley's Office for the History of Science and Technology. Born in Mexico City, he grew up in the exurbs north of Portland, Oregon, and now lives in Oakland.

On the Use of Psychedelics for Psychiatry

By Alexis Madrigal
Aug 30 2010, 6:23 PM ET Comment

We tend to associate psychedelic drugs with Timothy Leary and rock music, but there's an emerging evidence-based movement to (re)incorporate them into psychiatric practice. Science blogger Vaughan Bell describes his own experience and the science of ayahuasca.

Psychedelic drugs, mental health and brain science have traditionally made for a heated combination, but a recent scientific article, published in September's Nature Reviews Neuroscience, has attempted to more coolly assess the growing research on the potential of hallucinogens to treat depression and anxiety.

Lab studies and medical trials form a small but robust body of knowledge that reveal reliable benefits and promising future avenues. The dissociative anaesthetic ketamine has been found to lift mood - even in cases of severe of depression - while psilocybin, present across the world in mushrooms and fungi, has been shown to have anxiety reducing properties.

But while no serious bad reactions have happened during the trials, the full range of potential risks is still not fully understood, meaning the treatments remain firmly in the lab.
Read the full story at Mind Hacks.

Presented by

More at The Atlantic

The Risks of Romney's Anti-China Rhetoric The Economic Risks of Romney's Anti-China Rhetoric
We, the Web Kids We, the Web Kids
Picture of the Day: Giant Eddy Visible From Orbit Giant Eddy Visible From Orbit
Sleigh Bells' Positive Rock For Sleigh Bells, Style Is the Point
Blue-Collar Votes Will Make or Break Santorum in Michigan and Beyond Blue-Collar Votes Will Make or Break Santorum in Michigan

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
The Next Global Economies Reuters The Next Global Economies
Lessons from the BRICs — and a look at which developing countries are on the rise. Read more ›
View All Correspondents

The Biggest Story in Photos

More From Carnival 2012

Feb 22, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)